Download MendeleyiASPP mediates p53 selectivity through a modular mechanism fine-tuning DNA recognition.
Chen, S., Wu, J., Zhong, S., Li, Y., Zhang, P., Ma, J., Ren, J., Tan, Y., Wang, Y., Au, K.F., Siebold, C., Bond, G.L., Chen, Z., Lu, M., Jones, E.Y., Lu, X.(2019) Proc Natl Acad Sci U S A 116: 17470-17479
- PubMed: 31395738 Search on PubMedSearch on PubMed Central
- DOI: https://doi.org/10.1073/pnas.1909393116
- Primary Citation Related Structures:
6RZ3 - PubMed Abstract:
The most frequently mutated protein in human cancer is p53, a transcription factor (TF) that regulates myriad genes instrumental in diverse cellular outcomes including growth arrest and cell death. Cell context-dependent p53 modulation is critical for this life-or-death balance, yet remains incompletely understood. Here we identify sequence signatures enriched in genomic p53-binding sites modulated by the transcription cofactor iASPP. Moreover, our p53-iASPP crystal structure reveals that iASPP displaces the p53 L1 loop-which mediates sequence-specific interactions with the signature-corresponding base-without perturbing other DNA-recognizing modules of the p53 DNA-binding domain. A TF commonly uses multiple structural modules to recognize its cognate DNA, and thus this mechanism of a cofactor fine-tuning TF-DNA interactions through targeting a particular module is likely widespread. Previously, all tumor suppressors and oncoproteins that associate with the p53 DNA-binding domain-except the oncogenic E6 from human papillomaviruses (HPVs)-structurally cluster at the DNA-binding site of p53, complicating drug design. By contrast, iASPP inhibits p53 through a distinct surface overlapping the E6 footprint, opening prospects for p53-targeting precision medicine to improve cancer therapy.
- Ludwig Cancer Research, Nuffield Department of Medicine, University of Oxford, Oxford OX3 7DQ, United Kingdom.
Organizational Affiliation:
